#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Altered hippocampal volume and functional connectivity in males with Internet gaming disorder comparing to those with alcohol use disorder Internet gaming disorder (IGD) has been conceptualized as a behavioral addiction and shares clinical, neuropsychological, and personality characteristics with alcohol use disorder (AUD), but IGD dose not entail brain exposure to toxic agents, which renders it different from AUD.
1-1	0-7	Altered	_
1-2	8-19	hippocampal	_
1-3	20-26	volume	_
1-4	27-30	and	_
1-5	31-41	functional	_
1-6	42-54	connectivity	_
1-7	55-57	in	_
1-8	58-63	males	_
1-9	64-68	with	_
1-10	69-77	Internet	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
1-11	78-84	gaming	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
1-12	85-93	disorder	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
1-13	94-103	comparing	_
1-14	104-106	to	_
1-15	107-112	those	_
1-16	113-117	with	_
1-17	118-125	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-18	126-129	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-19	130-138	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-20	139-147	Internet	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
1-21	148-154	gaming	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
1-22	155-163	disorder	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
1-23	164-165	(	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
1-24	166-169	IGD	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
1-25	170-171	)	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
1-26	172-175	has	_
1-27	176-180	been	_
1-28	181-195	conceptualized	_
1-29	196-198	as	_
1-30	199-200	a	_
1-31	201-211	behavioral	_
1-32	212-221	addiction	_
1-33	222-225	and	_
1-34	226-232	shares	_
1-35	233-241	clinical	_
1-36	242-243	,	_
1-37	244-262	neuropsychological	_
1-38	263-264	,	_
1-39	265-268	and	_
1-40	269-280	personality	_
1-41	281-296	characteristics	_
1-42	297-301	with	_
1-43	302-309	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-44	310-313	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-45	314-322	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-46	323-324	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-47	325-328	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-48	329-330	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-49	331-332	,	_
1-50	333-336	but	_
1-51	337-340	IGD	_
1-52	341-345	dose	_
1-53	346-349	not	_
1-54	350-356	entail	_
1-55	357-362	brain	_
1-56	363-371	exposure	_
1-57	372-374	to	_
1-58	375-380	toxic	_
1-59	381-387	agents	_
1-60	388-389	,	_
1-61	390-395	which	_
1-62	396-403	renders	_
1-63	404-406	it	_
1-64	407-416	different	_
1-65	417-421	from	_
1-66	422-425	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
1-67	426-427	.	_

Text=To achieve a clear understanding of the neurobiological features of IGD, we aimed to identify morphological and functional changes in IGD and compare them with those in AUD.
2-1	428-430	To	_
2-2	431-438	achieve	_
2-3	439-440	a	_
2-4	441-446	clear	_
2-5	447-460	understanding	_
2-6	461-463	of	_
2-7	464-467	the	_
2-8	468-483	neurobiological	_
2-9	484-492	features	_
2-10	493-495	of	_
2-11	496-499	IGD	_
2-12	500-501	,	_
2-13	502-504	we	_
2-14	505-510	aimed	_
2-15	511-513	to	_
2-16	514-522	identify	_
2-17	523-536	morphological	_
2-18	537-540	and	_
2-19	541-551	functional	_
2-20	552-559	changes	_
2-21	560-562	in	_
2-22	563-566	IGD	_
2-23	567-570	and	_
2-24	571-578	compare	_
2-25	579-583	them	_
2-26	584-588	with	_
2-27	589-594	those	_
2-28	595-597	in	_
2-29	598-601	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
2-30	602-603	.	_

Text=Individuals with IGD showed larger volume in the hippocampus/amygdala and precuneus than healthy controls (HCs).
3-1	604-615	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-2	616-620	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-3	621-624	IGD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-4	625-631	showed	_
3-5	632-638	larger	_
3-6	639-645	volume	_
3-7	646-648	in	_
3-8	649-652	the	_
3-9	653-673	hippocampus/amygdala	_
3-10	674-677	and	_
3-11	678-687	precuneus	_
3-12	688-692	than	_
3-13	693-700	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-14	701-709	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-15	710-711	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-16	712-715	HCs	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-17	716-717	)	_
3-18	718-719	.	_

Text=The volume in the hippocampus positively correlated with the symptom severity of IGD.
4-1	720-723	The	_
4-2	724-730	volume	_
4-3	731-733	in	_
4-4	734-737	the	_
4-5	738-749	hippocampus	_
4-6	750-760	positively	_
4-7	761-771	correlated	_
4-8	772-776	with	_
4-9	777-780	the	_
4-10	781-788	symptom	_
4-11	789-797	severity	_
4-12	798-800	of	_
4-13	801-804	IGD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-14	805-806	.	_

Text=Moreover, functional connectivity analysis with the hippocampus/amygdala cluster revealed that the left ventromedial prefrontal cortex showed stronger functional connectivity in individuals with IGD compared to those with AUD.
5-1	807-815	Moreover	_
5-2	816-817	,	_
5-3	818-828	functional	_
5-4	829-841	connectivity	_
5-5	842-850	analysis	_
5-6	851-855	with	_
5-7	856-859	the	_
5-8	860-880	hippocampus/amygdala	_
5-9	881-888	cluster	_
5-10	889-897	revealed	_
5-11	898-902	that	_
5-12	903-906	the	_
5-13	907-911	left	_
5-14	912-924	ventromedial	_
5-15	925-935	prefrontal	_
5-16	936-942	cortex	_
5-17	943-949	showed	_
5-18	950-958	stronger	_
5-19	959-969	functional	_
5-20	970-982	connectivity	_
5-21	983-985	in	_
5-22	986-997	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-23	998-1002	with	_
5-24	1003-1006	IGD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-25	1007-1015	compared	_
5-26	1016-1018	to	_
5-27	1019-1024	those	_
5-28	1025-1029	with	_
5-29	1030-1033	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
5-30	1034-1035	.	_

Text=In contrast, individuals with AUD exhibited the smaller cerebellar volume and thinner medial frontal cortex than HCs.
6-1	1036-1038	In	_
6-2	1039-1047	contrast	_
6-3	1048-1049	,	_
6-4	1050-1061	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-5	1062-1066	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-6	1067-1070	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
6-7	1071-1080	exhibited	_
6-8	1081-1084	the	_
6-9	1085-1092	smaller	_
6-10	1093-1103	cerebellar	_
6-11	1104-1110	volume	_
6-12	1111-1114	and	_
6-13	1115-1122	thinner	_
6-14	1123-1129	medial	_
6-15	1130-1137	frontal	_
6-16	1138-1144	cortex	_
6-17	1145-1149	than	_
6-18	1150-1153	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-19	1154-1155	.	_

Text=The volume in the cerebellum correlated with impaired working memory function as well as duration of illness in AUD group.
7-1	1156-1159	The	_
7-2	1160-1166	volume	_
7-3	1167-1169	in	_
7-4	1170-1173	the	_
7-5	1174-1184	cerebellum	_
7-6	1185-1195	correlated	_
7-7	1196-1200	with	_
7-8	1201-1209	impaired	_
7-9	1210-1217	working	_
7-10	1218-1224	memory	_
7-11	1225-1233	function	_
7-12	1234-1236	as	_
7-13	1237-1241	well	_
7-14	1242-1244	as	_
7-15	1245-1253	duration	_
7-16	1254-1256	of	_
7-17	1257-1264	illness	_
7-18	1265-1267	in	_
7-19	1268-1271	AUD	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
7-20	1272-1277	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
7-21	1278-1279	.	_

Text=Findings suggested that altered volume and functional connectivity in the hippocampus/amygdala in IGD might be associated with abnormally enhanced memory process of gaming-related cues, while abnormal cortical changes and cognitive impairments in AUD might be associated with neurotoxic effects of alcohol.
8-1	1280-1288	Findings	_
8-2	1289-1298	suggested	_
8-3	1299-1303	that	_
8-4	1304-1311	altered	_
8-5	1312-1318	volume	_
8-6	1319-1322	and	_
8-7	1323-1333	functional	_
8-8	1334-1346	connectivity	_
8-9	1347-1349	in	_
8-10	1350-1353	the	_
8-11	1354-1374	hippocampus/amygdala	_
8-12	1375-1377	in	_
8-13	1378-1381	IGD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-14	1382-1387	might	_
8-15	1388-1390	be	_
8-16	1391-1401	associated	_
8-17	1402-1406	with	_
8-18	1407-1417	abnormally	_
8-19	1418-1426	enhanced	_
8-20	1427-1433	memory	_
8-21	1434-1441	process	_
8-22	1442-1444	of	_
8-23	1445-1459	gaming-related	_
8-24	1460-1464	cues	_
8-25	1465-1466	,	_
8-26	1467-1472	while	_
8-27	1473-1481	abnormal	_
8-28	1482-1490	cortical	_
8-29	1491-1498	changes	_
8-30	1499-1502	and	_
8-31	1503-1512	cognitive	_
8-32	1513-1524	impairments	_
8-33	1525-1527	in	_
8-34	1528-1531	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
8-35	1532-1537	might	_
8-36	1538-1540	be	_
8-37	1541-1551	associated	_
8-38	1552-1556	with	_
8-39	1557-1567	neurotoxic	_
8-40	1568-1575	effects	_
8-41	1576-1578	of	_
8-42	1579-1586	alcohol	_
8-43	1587-1588	.	_

Text=Methods Participants We enrolled 19 individuals diagnosed with IGD, 20 individuals diagnosed with AUD, and 25 HCs between 2013 and 2015.
9-1	1589-1596	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-2	1597-1609	Participants	_
9-3	1610-1612	We	_
9-4	1613-1621	enrolled	_
9-5	1622-1624	19	_
9-6	1625-1636	individuals	_
9-7	1637-1646	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-8	1647-1651	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-9	1652-1655	IGD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-10	1656-1657	,	_
9-11	1658-1660	20	_
9-12	1661-1672	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
9-13	1673-1682	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-14	1683-1687	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-15	1688-1691	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
9-16	1692-1693	,	_
9-17	1694-1697	and	_
9-18	1698-1700	25	_
9-19	1701-1704	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-20	1705-1712	between	_
9-21	1713-1717	2013	_
9-22	1718-1721	and	_
9-23	1722-1726	2015	_
9-24	1727-1728	.	_

Text=Since males have a higher potential to be addicted to Internet gaming than females do, we recruited only males.
10-1	1729-1734	Since	_
10-2	1735-1740	males	_
10-3	1741-1745	have	_
10-4	1746-1747	a	_
10-5	1748-1754	higher	_
10-6	1755-1764	potential	_
10-7	1765-1767	to	_
10-8	1768-1770	be	_
10-9	1771-1779	addicted	_
10-10	1780-1782	to	_
10-11	1783-1791	Internet	_
10-12	1792-1798	gaming	_
10-13	1799-1803	than	_
10-14	1804-1811	females	_
10-15	1812-1814	do	_
10-16	1815-1816	,	_
10-17	1817-1819	we	_
10-18	1820-1829	recruited	_
10-19	1830-1834	only	_
10-20	1835-1840	males	_
10-21	1841-1842	.	_

Text=All individuals with IGD or AUD were seeking treatment for excessive participation in Internet gaming or alcohol consumption and visited to the outpatient clinics of the SMG-SNU Boramae Medical Center.
11-1	1843-1846	All	_
11-2	1847-1858	individuals	_
11-3	1859-1863	with	_
11-4	1864-1867	IGD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
11-5	1868-1870	or	_
11-6	1871-1874	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
11-7	1875-1879	were	_
11-8	1880-1887	seeking	_
11-9	1888-1897	treatment	_
11-10	1898-1901	for	_
11-11	1902-1911	excessive	_
11-12	1912-1925	participation	_
11-13	1926-1928	in	_
11-14	1929-1937	Internet	_
11-15	1938-1944	gaming	_
11-16	1945-1947	or	_
11-17	1948-1955	alcohol	_
11-18	1956-1967	consumption	_
11-19	1968-1971	and	_
11-20	1972-1979	visited	_
11-21	1980-1982	to	_
11-22	1983-1986	the	_
11-23	1987-1997	outpatient	_
11-24	1998-2005	clinics	_
11-25	2006-2008	of	_
11-26	2009-2012	the	_
11-27	2013-2020	SMG-SNU	_
11-28	2021-2028	Boramae	_
11-29	2029-2036	Medical	_
11-30	2037-2043	Center	_
11-31	2044-2045	.	_

Text=HCs were recruited through an advertisement posted on the SMG-SNU Boramae Medical Center.
12-1	2046-2049	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
12-2	2050-2054	were	_
12-3	2055-2064	recruited	_
12-4	2065-2072	through	_
12-5	2073-2075	an	_
12-6	2076-2089	advertisement	_
12-7	2090-2096	posted	_
12-8	2097-2099	on	_
12-9	2100-2103	the	_
12-10	2104-2111	SMG-SNU	_
12-11	2112-2119	Boramae	_
12-12	2120-2127	Medical	_
12-13	2128-2134	Center	_
12-14	2135-2136	.	_

Text=IGD was diagnosed according to the DSM-IV criteria and the severity of IGD was assessed using IAT.
13-1	2137-2140	IGD	_
13-2	2141-2144	was	_
13-3	2145-2154	diagnosed	_
13-4	2155-2164	according	_
13-5	2165-2167	to	_
13-6	2168-2171	the	_
13-7	2172-2178	DSM-IV	_
13-8	2179-2187	criteria	_
13-9	2188-2191	and	_
13-10	2192-2195	the	_
13-11	2196-2204	severity	_
13-12	2205-2207	of	_
13-13	2208-2211	IGD	_
13-14	2212-2215	was	_
13-15	2216-2224	assessed	_
13-16	2225-2230	using	_
13-17	2231-2234	IAT	_
13-18	2235-2236	.	_

Text=We included subjects with IAT scores of at least 50 who spent more than 4 hours per day and 30 hours per week involved in Internet gaming.
14-1	2237-2239	We	_
14-2	2240-2248	included	_
14-3	2249-2257	subjects	_
14-4	2258-2262	with	_
14-5	2263-2266	IAT	_
14-6	2267-2273	scores	_
14-7	2274-2276	of	_
14-8	2277-2279	at	_
14-9	2280-2285	least	_
14-10	2286-2288	50	_
14-11	2289-2292	who	_
14-12	2293-2298	spent	_
14-13	2299-2303	more	_
14-14	2304-2308	than	_
14-15	2309-2310	4	_
14-16	2311-2316	hours	_
14-17	2317-2320	per	_
14-18	2321-2324	day	_
14-19	2325-2328	and	_
14-20	2329-2331	30	_
14-21	2332-2337	hours	_
14-22	2338-2341	per	_
14-23	2342-2346	week	_
14-24	2347-2355	involved	_
14-25	2356-2358	in	_
14-26	2359-2367	Internet	_
14-27	2368-2374	gaming	_
14-28	2375-2376	.	_

Text=The mean IAT score of the individuals with IGD was 76.3 ± 7.8, and their mean time spent on Internet gaming was 7.7 ± 3.5 hours per day.
15-1	2377-2380	The	_
15-2	2381-2385	mean	_
15-3	2386-2389	IAT	_
15-4	2390-2395	score	_
15-5	2396-2398	of	_
15-6	2399-2402	the	_
15-7	2403-2414	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-8	2415-2419	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-9	2420-2423	IGD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-10	2424-2427	was	_
15-11	2428-2432	76.3	_
15-12	2433-2434	±	_
15-13	2435-2438	7.8	_
15-14	2439-2440	,	_
15-15	2441-2444	and	_
15-16	2445-2450	their	_
15-17	2451-2455	mean	_
15-18	2456-2460	time	_
15-19	2461-2466	spent	_
15-20	2467-2469	on	_
15-21	2470-2478	Internet	_
15-22	2479-2485	gaming	_
15-23	2486-2489	was	_
15-24	2490-2493	7.7	_
15-25	2494-2495	±	_
15-26	2496-2499	3.5	_
15-27	2500-2505	hours	_
15-28	2506-2509	per	_
15-29	2510-2513	day	_
15-30	2514-2515	.	_

Text=AUD was diagnosed based on the SCID and, the severity of AUD was assessed using the Korean version of the Alcohol Use Disorder Identification Test (AUDIT-K).
16-1	2516-2519	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
16-2	2520-2523	was	_
16-3	2524-2533	diagnosed	_
16-4	2534-2539	based	_
16-5	2540-2542	on	_
16-6	2543-2546	the	_
16-7	2547-2551	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-8	2552-2555	and	_
16-9	2556-2557	,	_
16-10	2558-2561	the	_
16-11	2562-2570	severity	_
16-12	2571-2573	of	_
16-13	2574-2577	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
16-14	2578-2581	was	_
16-15	2582-2590	assessed	_
16-16	2591-2596	using	_
16-17	2597-2600	the	_
16-18	2601-2607	Korean	_
16-19	2608-2615	version	_
16-20	2616-2618	of	_
16-21	2619-2622	the	_
16-22	2623-2630	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
16-23	2631-2634	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
16-24	2635-2643	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
16-25	2644-2658	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
16-26	2659-2663	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
16-27	2664-2665	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
16-28	2666-2673	AUDIT-K	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
16-29	2674-2675	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
16-30	2676-2677	.	_

Text=The mean AUDIT-K score of the individuals with AUD was 24.0 ± 5.3, and their mean quantity of alcohol consumed per day was 8.3 ± 2.5 standard drinks.
17-1	2678-2681	The	_
17-2	2682-2686	mean	_
17-3	2687-2694	AUDIT-K	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
17-4	2695-2700	score	_
17-5	2701-2703	of	_
17-6	2704-2707	the	_
17-7	2708-2719	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
17-8	2720-2724	with	_
17-9	2725-2728	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
17-10	2729-2732	was	_
17-11	2733-2737	24.0	_
17-12	2738-2739	±	_
17-13	2740-2743	5.3	_
17-14	2744-2745	,	_
17-15	2746-2749	and	_
17-16	2750-2755	their	_
17-17	2756-2760	mean	_
17-18	2761-2769	quantity	_
17-19	2770-2772	of	_
17-20	2773-2780	alcohol	_
17-21	2781-2789	consumed	_
17-22	2790-2793	per	_
17-23	2794-2797	day	_
17-24	2798-2801	was	_
17-25	2802-2805	8.3	_
17-26	2806-2807	±	_
17-27	2808-2811	2.5	_
17-28	2812-2820	standard	_
17-29	2821-2827	drinks	_
17-30	2828-2829	.	_

Text=Individuals with AUD were abstinent from alcohol at least 2 weeks before participation in the present study.
18-1	2830-2841	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
18-2	2842-2846	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
18-3	2847-2850	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
18-4	2851-2855	were	_
18-5	2856-2865	abstinent	_
18-6	2866-2870	from	_
18-7	2871-2878	alcohol	_
18-8	2879-2881	at	_
18-9	2882-2887	least	_
18-10	2888-2889	2	_
18-11	2890-2895	weeks	_
18-12	2896-2902	before	_
18-13	2903-2916	participation	_
18-14	2917-2919	in	_
18-15	2920-2923	the	_
18-16	2924-2931	present	_
18-17	2932-2937	study	_
18-18	2938-2939	.	_

Text=Alcohol abstinence was confirmed self-reports and reports from caregivers.
19-1	2940-2947	Alcohol	_
19-2	2948-2958	abstinence	_
19-3	2959-2962	was	_
19-4	2963-2972	confirmed	_
19-5	2973-2985	self-reports	_
19-6	2986-2989	and	_
19-7	2990-2997	reports	_
19-8	2998-3002	from	_
19-9	3003-3013	caregivers	_
19-10	3014-3015	.	_

Text=We regarded these reports as reliable because the participants attended regular follow-up visits to our outpatient clinic and showed good adherence to treatment.
20-1	3016-3018	We	_
20-2	3019-3027	regarded	_
20-3	3028-3033	these	_
20-4	3034-3041	reports	_
20-5	3042-3044	as	_
20-6	3045-3053	reliable	_
20-7	3054-3061	because	_
20-8	3062-3065	the	_
20-9	3066-3078	participants	_
20-10	3079-3087	attended	_
20-11	3088-3095	regular	_
20-12	3096-3105	follow-up	_
20-13	3106-3112	visits	_
20-14	3113-3115	to	_
20-15	3116-3119	our	_
20-16	3120-3130	outpatient	_
20-17	3131-3137	clinic	_
20-18	3138-3141	and	_
20-19	3142-3148	showed	_
20-20	3149-3153	good	_
20-21	3154-3163	adherence	_
20-22	3164-3166	to	_
20-23	3167-3176	treatment	_
20-24	3177-3178	.	_

Text=The SCID was used to identify past and current psychiatric illnesses of addiction groups.
21-1	3179-3182	The	_
21-2	3183-3187	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-3	3188-3191	was	_
21-4	3192-3196	used	_
21-5	3197-3199	to	_
21-6	3200-3208	identify	_
21-7	3209-3213	past	_
21-8	3214-3217	and	_
21-9	3218-3225	current	_
21-10	3226-3237	psychiatric	_
21-11	3238-3247	illnesses	_
21-12	3248-3250	of	_
21-13	3251-3260	addiction	_
21-14	3261-3267	groups	_
21-15	3268-3269	.	_

Text=Individuals with AUD and HCs used the Internet less than 2 hours per day and mean IAT score of AUD group was 29.6 ± 5.7, and that of HCs was 26.0 ± 13.1.
22-1	3270-3281	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
22-2	3282-3286	with	_
22-3	3287-3290	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
22-4	3291-3294	and	_
22-5	3295-3298	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-6	3299-3303	used	_
22-7	3304-3307	the	_
22-8	3308-3316	Internet	_
22-9	3317-3321	less	_
22-10	3322-3326	than	_
22-11	3327-3328	2	_
22-12	3329-3334	hours	_
22-13	3335-3338	per	_
22-14	3339-3342	day	_
22-15	3343-3346	and	_
22-16	3347-3351	mean	_
22-17	3352-3355	IAT	_
22-18	3356-3361	score	_
22-19	3362-3364	of	_
22-20	3365-3368	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
22-21	3369-3374	group	_
22-22	3375-3378	was	_
22-23	3379-3383	29.6	_
22-24	3384-3385	±	_
22-25	3386-3389	5.7	_
22-26	3390-3391	,	_
22-27	3392-3395	and	_
22-28	3396-3400	that	_
22-29	3401-3403	of	_
22-30	3404-3407	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-31	3408-3411	was	_
22-32	3412-3416	26.0	_
22-33	3417-3418	±	_
22-34	3419-3423	13.1	_
22-35	3424-3425	.	_

Text=Individuals with IGD and HCs had no lifetime history of AUD and drank fewer than 14 standard drinks per week and fewer than 4 standard drinks per occasion.
23-1	3426-3437	Individuals	_
23-2	3438-3442	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
23-3	3443-3446	IGD	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
23-4	3447-3450	and	_
23-5	3451-3454	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
23-6	3455-3458	had	_
23-7	3459-3461	no	_
23-8	3462-3470	lifetime	_
23-9	3471-3478	history	_
23-10	3479-3481	of	_
23-11	3482-3485	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
23-12	3486-3489	and	_
23-13	3490-3495	drank	_
23-14	3496-3501	fewer	_
23-15	3502-3506	than	_
23-16	3507-3509	14	_
23-17	3510-3518	standard	_
23-18	3519-3525	drinks	_
23-19	3526-3529	per	_
23-20	3530-3534	week	_
23-21	3535-3538	and	_
23-22	3539-3544	fewer	_
23-23	3545-3549	than	_
23-24	3550-3551	4	_
23-25	3552-3560	standard	_
23-26	3561-3567	drinks	_
23-27	3568-3571	per	_
23-28	3572-3580	occasion	_
23-29	3581-3582	.	_

Text=Mean AUDIT-K of IGD was 4.0 ± 2.8 and, that of HCs was 5.9 ± 3.3.
24-1	3583-3587	Mean	_
24-2	3588-3595	AUDIT-K	_
24-3	3596-3598	of	_
24-4	3599-3602	IGD	_
24-5	3603-3606	was	_
24-6	3607-3610	4.0	_
24-7	3611-3612	±	_
24-8	3613-3616	2.8	_
24-9	3617-3620	and	_
24-10	3621-3622	,	_
24-11	3623-3627	that	_
24-12	3628-3630	of	_
24-13	3631-3634	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
24-14	3635-3638	was	_
24-15	3639-3642	5.9	_
24-16	3643-3644	±	_
24-17	3645-3648	3.3	_
24-18	3649-3650	.	_

Text=Exclusion criteria included a history of significant head injury, seizure disorder, mental retardation, other substance abuse (except smoking) or psychotic disorder and IQ score estimated by the Korean version of the Wechsler Adult Intelligence Scale (WAIS-III) below 80.
25-1	3651-3660	Exclusion	_
25-2	3661-3669	criteria	_
25-3	3670-3678	included	_
25-4	3679-3680	a	_
25-5	3681-3688	history	_
25-6	3689-3691	of	_
25-7	3692-3703	significant	_
25-8	3704-3708	head	_
25-9	3709-3715	injury	_
25-10	3716-3717	,	_
25-11	3718-3725	seizure	_
25-12	3726-3734	disorder	_
25-13	3735-3736	,	_
25-14	3737-3743	mental	_
25-15	3744-3755	retardation	_
25-16	3756-3757	,	_
25-17	3758-3763	other	_
25-18	3764-3773	substance	_
25-19	3774-3779	abuse	_
25-20	3780-3781	(	_
25-21	3782-3788	except	_
25-22	3789-3796	smoking	_
25-23	3797-3798	)	_
25-24	3799-3801	or	_
25-25	3802-3811	psychotic	_
25-26	3812-3820	disorder	_
25-27	3821-3824	and	_
25-28	3825-3827	IQ	_
25-29	3828-3833	score	_
25-30	3834-3843	estimated	_
25-31	3844-3846	by	_
25-32	3847-3850	the	_
25-33	3851-3857	Korean	_
25-34	3858-3865	version	_
25-35	3866-3868	of	_
25-36	3869-3872	the	_
25-37	3873-3881	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
25-38	3882-3887	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
25-39	3888-3900	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
25-40	3901-3906	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
25-41	3907-3908	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
25-42	3909-3917	WAIS-III	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
25-43	3918-3919	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
25-44	3920-3925	below	_
25-45	3926-3928	80	_
25-46	3929-3930	.	_

Text=Individuals with both IGD and AUD were excluded from participation in this study.
26-1	3931-3942	Individuals	_
26-2	3943-3947	with	_
26-3	3948-3952	both	_
26-4	3953-3956	IGD	_
26-5	3957-3960	and	_
26-6	3961-3964	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
26-7	3965-3969	were	_
26-8	3970-3978	excluded	_
26-9	3979-3983	from	_
26-10	3984-3997	participation	_
26-11	3998-4000	in	_
26-12	4001-4005	this	_
26-13	4006-4011	study	_
26-14	4012-4013	.	_

Text=All participants completed the BDI, BAI, and BIS-11.
27-1	4014-4017	All	_
27-2	4018-4030	participants	_
27-3	4031-4040	completed	_
27-4	4041-4044	the	_
27-5	4045-4048	BDI	_
27-6	4049-4050	,	_
27-7	4051-4054	BAI	_
27-8	4055-4056	,	_
27-9	4057-4060	and	_
27-10	4061-4067	BIS-11	_
27-11	4068-4069	.	_

Text=The study protocol was approved by the Institutional Review Board of the SMG-SNU Boramae Medical Center and all methods were performed in accordance with the approved guidelines and the Declaration of Helsinki.
28-1	4070-4073	The	_
28-2	4074-4079	study	_
28-3	4080-4088	protocol	_
28-4	4089-4092	was	_
28-5	4093-4101	approved	_
28-6	4102-4104	by	_
28-7	4105-4108	the	_
28-8	4109-4122	Institutional	_
28-9	4123-4129	Review	_
28-10	4130-4135	Board	_
28-11	4136-4138	of	_
28-12	4139-4142	the	_
28-13	4143-4150	SMG-SNU	_
28-14	4151-4158	Boramae	_
28-15	4159-4166	Medical	_
28-16	4167-4173	Center	_
28-17	4174-4177	and	_
28-18	4178-4181	all	_
28-19	4182-4189	methods	_
28-20	4190-4194	were	_
28-21	4195-4204	performed	_
28-22	4205-4207	in	_
28-23	4208-4218	accordance	_
28-24	4219-4223	with	_
28-25	4224-4227	the	_
28-26	4228-4236	approved	_
28-27	4237-4247	guidelines	_
28-28	4248-4251	and	_
28-29	4252-4255	the	_
28-30	4256-4267	Declaration	_
28-31	4268-4270	of	_
28-32	4271-4279	Helsinki	_
28-33	4280-4281	.	_

Text=All subjects gave written informed consent before enrolling in this study after a detailed explanation of the procedure.
29-1	4282-4285	All	_
29-2	4286-4294	subjects	_
29-3	4295-4299	gave	_
29-4	4300-4307	written	_
29-5	4308-4316	informed	_
29-6	4317-4324	consent	_
29-7	4325-4331	before	_
29-8	4332-4341	enrolling	_
29-9	4342-4344	in	_
29-10	4345-4349	this	_
29-11	4350-4355	study	_
29-12	4356-4361	after	_
29-13	4362-4363	a	_
29-14	4364-4372	detailed	_
29-15	4373-4384	explanation	_
29-16	4385-4387	of	_
29-17	4388-4391	the	_
29-18	4392-4401	procedure	_
29-19	4402-4403	.	_

Text=Image acquisition We used a 3.0 T MR system (Achieva, Philips Medical Systems, Best, The Netherlands) to acquire a high-resolution T1-anatomical brain image with a 3D T1-weighted turbo field echo (T1TFE) sequence (TR = 9.9 ms, TE = 4.6 ms, flip angle = 8°, field of view = 220 × 220, 180 slices, thickness = 1 mm, voxel size = 0.98 mm × 0.98 mm × 1 mm) and whole-brain resting-state functional image using a T2 * -weighted echo-planar imaging sequence (TR = 2700 ms, TE = 35 ms, flip angle = 90°, field of view = 220 × 220, 35 slices, thickness = 4 mm, voxel size = 1.53 mm × 1.53 mm × 4 mm, 180 volumes).
30-1	4404-4409	Image	_
30-2	4410-4421	acquisition	_
30-3	4422-4424	We	_
30-4	4425-4429	used	_
30-5	4430-4431	a	_
30-6	4432-4435	3.0	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
30-7	4436-4437	T	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
30-8	4438-4440	MR	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
30-9	4441-4447	system	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
30-10	4448-4449	(	_
30-11	4450-4457	Achieva	_
30-12	4458-4459	,	_
30-13	4460-4467	Philips	_
30-14	4468-4475	Medical	_
30-15	4476-4483	Systems	_
30-16	4484-4485	,	_
30-17	4486-4490	Best	_
30-18	4491-4492	,	_
30-19	4493-4496	The	_
30-20	4497-4508	Netherlands	_
30-21	4509-4510	)	_
30-22	4511-4513	to	_
30-23	4514-4521	acquire	_
30-24	4522-4523	a	_
30-25	4524-4539	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
30-26	4540-4553	T1-anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-27	4554-4559	brain	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-28	4560-4565	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-29	4566-4570	with	_
30-30	4571-4572	a	_
30-31	4573-4575	3D	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-32	4576-4587	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-33	4588-4593	turbo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-34	4594-4599	field	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-35	4600-4604	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-36	4605-4606	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-37	4607-4612	T1TFE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-38	4613-4614	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-39	4615-4623	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-40	4624-4625	(	_
30-41	4626-4628	TR	_
30-42	4629-4630	=	_
30-43	4631-4634	9.9	_
30-44	4635-4637	ms	_
30-45	4638-4639	,	_
30-46	4640-4642	TE	_
30-47	4643-4644	=	_
30-48	4645-4648	4.6	_
30-49	4649-4651	ms	_
30-50	4652-4653	,	_
30-51	4654-4658	flip	_
30-52	4659-4664	angle	_
30-53	4665-4666	=	_
30-54	4667-4669	8°	_
30-55	4670-4671	,	_
30-56	4672-4677	field	_
30-57	4678-4680	of	_
30-58	4681-4685	view	_
30-59	4686-4687	=	_
30-60	4688-4691	220	_
30-61	4692-4693	×	_
30-62	4694-4697	220	_
30-63	4698-4699	,	_
30-64	4700-4703	180	_
30-65	4704-4710	slices	_
30-66	4711-4712	,	_
30-67	4713-4722	thickness	_
30-68	4723-4724	=	_
30-69	4725-4726	1	_
30-70	4727-4729	mm	_
30-71	4730-4731	,	_
30-72	4732-4737	voxel	_
30-73	4738-4742	size	_
30-74	4743-4744	=	_
30-75	4745-4749	0.98	_
30-76	4750-4752	mm	_
30-77	4753-4754	×	_
30-78	4755-4759	0.98	_
30-79	4760-4762	mm	_
30-80	4763-4764	×	_
30-81	4765-4766	1	_
30-82	4767-4769	mm	_
30-83	4770-4771	)	_
30-84	4772-4775	and	_
30-85	4776-4787	whole-brain	_
30-86	4788-4801	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-87	4802-4812	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-88	4813-4818	image	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-89	4819-4824	using	_
30-90	4825-4826	a	_
30-91	4827-4829	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-92	4830-4831	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-93	4832-4841	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-94	4842-4853	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-95	4854-4861	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-96	4862-4870	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-97	4871-4872	(	_
30-98	4873-4875	TR	_
30-99	4876-4877	=	_
30-100	4878-4882	2700	_
30-101	4883-4885	ms	_
30-102	4886-4887	,	_
30-103	4888-4890	TE	_
30-104	4891-4892	=	_
30-105	4893-4895	35	_
30-106	4896-4898	ms	_
30-107	4899-4900	,	_
30-108	4901-4905	flip	_
30-109	4906-4911	angle	_
30-110	4912-4913	=	_
30-111	4914-4917	90°	_
30-112	4918-4919	,	_
30-113	4920-4925	field	_
30-114	4926-4928	of	_
30-115	4929-4933	view	_
30-116	4934-4935	=	_
30-117	4936-4939	220	_
30-118	4940-4941	×	_
30-119	4942-4945	220	_
30-120	4946-4947	,	_
30-121	4948-4950	35	_
30-122	4951-4957	slices	_
30-123	4958-4959	,	_
30-124	4960-4969	thickness	_
30-125	4970-4971	=	_
30-126	4972-4973	4	_
30-127	4974-4976	mm	_
30-128	4977-4978	,	_
30-129	4979-4984	voxel	_
30-130	4985-4989	size	_
30-131	4990-4991	=	_
30-132	4992-4996	1.53	_
30-133	4997-4999	mm	_
30-134	5000-5001	×	_
30-135	5002-5006	1.53	_
30-136	5007-5009	mm	_
30-137	5010-5011	×	_
30-138	5012-5013	4	_
30-139	5014-5016	mm	_
30-140	5017-5018	,	_
30-141	5019-5022	180	_
30-142	5023-5030	volumes	_
30-143	5031-5032	)	_
30-144	5033-5034	.	_

Text=During functional MRI (fMRI) scanning, participants were instructed to rest with their eyes open, not to sleep, and not to think about anything in particular.
31-1	5035-5041	During	_
31-2	5042-5052	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
31-3	5053-5056	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
31-4	5057-5058	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
31-5	5059-5063	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
31-6	5064-5065	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
31-7	5066-5074	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
31-8	5075-5076	,	_
31-9	5077-5089	participants	_
31-10	5090-5094	were	_
31-11	5095-5105	instructed	_
31-12	5106-5108	to	_
31-13	5109-5113	rest	_
31-14	5114-5118	with	_
31-15	5119-5124	their	_
31-16	5125-5129	eyes	_
31-17	5130-5134	open	_
31-18	5135-5136	,	_
31-19	5137-5140	not	_
31-20	5141-5143	to	_
31-21	5144-5149	sleep	_
31-22	5150-5151	,	_
31-23	5152-5155	and	_
31-24	5156-5159	not	_
31-25	5160-5162	to	_
31-26	5163-5168	think	_
31-27	5169-5174	about	_
31-28	5175-5183	anything	_
31-29	5184-5186	in	_
31-30	5187-5197	particular	_
31-31	5198-5199	.	_

Text=Image processing Cortical volume VBM was performed using SPM8 (http//www.fil.ion.ucl.ac.uk/spm/software/spm8) implemented in Matlab 7.11 (The MathWorks, Inc. Natick, MA, USA).
32-1	5200-5205	Image	_
32-2	5206-5216	processing	_
32-3	5217-5225	Cortical	_
32-4	5226-5232	volume	_
32-5	5233-5236	VBM	_
32-6	5237-5240	was	_
32-7	5241-5250	performed	_
32-8	5251-5256	using	_
32-9	5257-5261	SPM8	_
32-10	5262-5263	(	_
32-11	5264-5309	http//www.fil.ion.ucl.ac.uk/spm/software/spm8	_
32-12	5310-5311	)	_
32-13	5312-5323	implemented	_
32-14	5324-5326	in	_
32-15	5327-5333	Matlab	_
32-16	5334-5338	7.11	_
32-17	5339-5340	(	_
32-18	5341-5344	The	_
32-19	5345-5354	MathWorks	_
32-20	5355-5356	,	_
32-21	5357-5361	Inc.	_
32-22	5362-5368	Natick	_
32-23	5369-5370	,	_
32-24	5371-5373	MA	_
32-25	5374-5375	,	_
32-26	5376-5379	USA	_
32-27	5380-5381	)	_
32-28	5382-5383	.	_

Text=Each anatomical MR image was segmented and non-linearly normalized to a standard template using the DARTEL algorithm provided in SPM8.
33-1	5384-5388	Each	_
33-2	5389-5399	anatomical	_
33-3	5400-5402	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-4	5403-5408	image	_
33-5	5409-5412	was	_
33-6	5413-5422	segmented	_
33-7	5423-5426	and	_
33-8	5427-5439	non-linearly	_
33-9	5440-5450	normalized	_
33-10	5451-5453	to	_
33-11	5454-5455	a	_
33-12	5456-5464	standard	_
33-13	5465-5473	template	_
33-14	5474-5479	using	_
33-15	5480-5483	the	_
33-16	5484-5490	DARTEL	_
33-17	5491-5500	algorithm	_
33-18	5501-5509	provided	_
33-19	5510-5512	in	_
33-20	5513-5517	SPM8	_
33-21	5518-5519	.	_

Text=The spatially normalized images were then rescaled using the Jacobian determinants of the deformations to preserve relative tissue volumes and smoothed using an 8-mm full-width half-maximum (FWHM) Gaussian kernel.
34-1	5520-5523	The	_
34-2	5524-5533	spatially	_
34-3	5534-5544	normalized	_
34-4	5545-5551	images	_
34-5	5552-5556	were	_
34-6	5557-5561	then	_
34-7	5562-5570	rescaled	_
34-8	5571-5576	using	_
34-9	5577-5580	the	_
34-10	5581-5589	Jacobian	_
34-11	5590-5602	determinants	_
34-12	5603-5605	of	_
34-13	5606-5609	the	_
34-14	5610-5622	deformations	_
34-15	5623-5625	to	_
34-16	5626-5634	preserve	_
34-17	5635-5643	relative	_
34-18	5644-5650	tissue	_
34-19	5651-5658	volumes	_
34-20	5659-5662	and	_
34-21	5663-5671	smoothed	_
34-22	5672-5677	using	_
34-23	5678-5680	an	_
34-24	5681-5685	8-mm	_
34-25	5686-5696	full-width	_
34-26	5697-5709	half-maximum	_
34-27	5710-5711	(	_
34-28	5712-5716	FWHM	_
34-29	5717-5718	)	_
34-30	5719-5727	Gaussian	_
34-31	5728-5734	kernel	_
34-32	5735-5736	.	_

Text=Cortical thickness FreeSurfer imaging analysis suite (http: //surfer.nmr.mgh.harvard.edu/; version 5.1.0) was used to estimate cortical thickness.
35-1	5737-5745	Cortical	_
35-2	5746-5755	thickness	_
35-3	5756-5766	FreeSurfer	_
35-4	5767-5774	imaging	_
35-5	5775-5783	analysis	_
35-6	5784-5789	suite	_
35-7	5790-5791	(	_
35-8	5792-5796	http	_
35-9	5797-5798	:	_
35-10	5799-5828	//surfer.nmr.mgh.harvard.edu/	_
35-11	5829-5830	;	_
35-12	5831-5838	version	_
35-13	5839-5844	5.1.0	_
35-14	5845-5846	)	_
35-15	5847-5850	was	_
35-16	5851-5855	used	_
35-17	5856-5858	to	_
35-18	5859-5867	estimate	_
35-19	5868-5876	cortical	_
35-20	5877-5886	thickness	_
35-21	5887-5888	.	_

Text=The local cortical thickness was measured on the basis of the difference between the position of equivalent vertices in the pial and gray–white matter surfaces.
36-1	5889-5892	The	_
36-2	5893-5898	local	_
36-3	5899-5907	cortical	_
36-4	5908-5917	thickness	_
36-5	5918-5921	was	_
36-6	5922-5930	measured	_
36-7	5931-5933	on	_
36-8	5934-5937	the	_
36-9	5938-5943	basis	_
36-10	5944-5946	of	_
36-11	5947-5950	the	_
36-12	5951-5961	difference	_
36-13	5962-5969	between	_
36-14	5970-5973	the	_
36-15	5974-5982	position	_
36-16	5983-5985	of	_
36-17	5986-5996	equivalent	_
36-18	5997-6005	vertices	_
36-19	6006-6008	in	_
36-20	6009-6012	the	_
36-21	6013-6017	pial	_
36-22	6018-6021	and	_
36-23	6022-6032	gray–white	_
36-24	6033-6039	matter	_
36-25	6040-6048	surfaces	_
36-26	6049-6050	.	_

Text=The details of these procedures have been extensively described in a prior publication.
37-1	6051-6054	The	_
37-2	6055-6062	details	_
37-3	6063-6065	of	_
37-4	6066-6071	these	_
37-5	6072-6082	procedures	_
37-6	6083-6087	have	_
37-7	6088-6092	been	_
37-8	6093-6104	extensively	_
37-9	6105-6114	described	_
37-10	6115-6117	in	_
37-11	6118-6119	a	_
37-12	6120-6125	prior	_
37-13	6126-6137	publication	_
37-14	6138-6139	.	_

Text=Segmented volumes were visually inspected, and the appropriate manual corrections were performed.
38-1	6140-6149	Segmented	_
38-2	6150-6157	volumes	_
38-3	6158-6162	were	_
38-4	6163-6171	visually	_
38-5	6172-6181	inspected	_
38-6	6182-6183	,	_
38-7	6184-6187	and	_
38-8	6188-6191	the	_
38-9	6192-6203	appropriate	_
38-10	6204-6210	manual	_
38-11	6211-6222	corrections	_
38-12	6223-6227	were	_
38-13	6228-6237	performed	_
38-14	6238-6239	.	_

Text=To obtain cortical thickness difference maps, the data were smoothed on the surface with a 10-mm FWHM Gaussian kernel.
39-1	6240-6242	To	_
39-2	6243-6249	obtain	_
39-3	6250-6258	cortical	_
39-4	6259-6268	thickness	_
39-5	6269-6279	difference	_
39-6	6280-6284	maps	_
39-7	6285-6286	,	_
39-8	6287-6290	the	_
39-9	6291-6295	data	_
39-10	6296-6300	were	_
39-11	6301-6309	smoothed	_
39-12	6310-6312	on	_
39-13	6313-6316	the	_
39-14	6317-6324	surface	_
39-15	6325-6329	with	_
39-16	6330-6331	a	_
39-17	6332-6337	10-mm	_
39-18	6338-6342	FWHM	_
39-19	6343-6351	Gaussian	_
39-20	6352-6358	kernel	_
39-21	6359-6360	.	_

Text=Functional connectivity Image preprocessing and statistical analysis were carried out using SPM8 and DPARSF (Data Processing Assistant for Resting-State fMRI, www.restfmri.net), based on MATLAB toolbox.
40-1	6361-6371	Functional	_
40-2	6372-6384	connectivity	_
40-3	6385-6390	Image	_
40-4	6391-6404	preprocessing	_
40-5	6405-6408	and	_
40-6	6409-6420	statistical	_
40-7	6421-6429	analysis	_
40-8	6430-6434	were	_
40-9	6435-6442	carried	_
40-10	6443-6446	out	_
40-11	6447-6452	using	_
40-12	6453-6457	SPM8	_
40-13	6458-6461	and	_
40-14	6462-6468	DPARSF	_
40-15	6469-6470	(	_
40-16	6471-6475	Data	_
40-17	6476-6486	Processing	_
40-18	6487-6496	Assistant	_
40-19	6497-6500	for	_
40-20	6501-6514	Resting-State	_
40-21	6515-6519	fMRI	_
40-22	6520-6521	,	_
40-23	6522-6538	www.restfmri.net	_
40-24	6539-6540	)	_
40-25	6541-6542	,	_
40-26	6543-6548	based	_
40-27	6549-6551	on	_
40-28	6552-6558	MATLAB	_
40-29	6559-6566	toolbox	_
40-30	6567-6568	.	_

Text=The first 10 volumes of the functional time series were discarded.
41-1	6569-6572	The	_
41-2	6573-6578	first	_
41-3	6579-6581	10	_
41-4	6582-6589	volumes	_
41-5	6590-6592	of	_
41-6	6593-6596	the	_
41-7	6597-6607	functional	_
41-8	6608-6612	time	_
41-9	6613-6619	series	_
41-10	6620-6624	were	_
41-11	6625-6634	discarded	_
41-12	6635-6636	.	_

Text=The remaining 170 volumes were subjected to slice timing correction, and to realigning with a six-parameter spatial transformation.
42-1	6637-6640	The	_
42-2	6641-6650	remaining	_
42-3	6651-6654	170	_
42-4	6655-6662	volumes	_
42-5	6663-6667	were	_
42-6	6668-6677	subjected	_
42-7	6678-6680	to	_
42-8	6681-6686	slice	_
42-9	6687-6693	timing	_
42-10	6694-6704	correction	_
42-11	6705-6706	,	_
42-12	6707-6710	and	_
42-13	6711-6713	to	_
42-14	6714-6724	realigning	_
42-15	6725-6729	with	_
42-16	6730-6731	a	_
42-17	6732-6745	six-parameter	_
42-18	6746-6753	spatial	_
42-19	6754-6768	transformation	_
42-20	6769-6770	.	_

Text=Data from participants with head-motion exceeding 2.0 mm of maximal rotation and 2.0° of any angular motion during the scan were eliminated from the analysis.
43-1	6771-6775	Data	_
43-2	6776-6780	from	_
43-3	6781-6793	participants	_
43-4	6794-6798	with	_
43-5	6799-6810	head-motion	_
43-6	6811-6820	exceeding	_
43-7	6821-6824	2.0	_
43-8	6825-6827	mm	_
43-9	6828-6830	of	_
43-10	6831-6838	maximal	_
43-11	6839-6847	rotation	_
43-12	6848-6851	and	_
43-13	6852-6856	2.0°	_
43-14	6857-6859	of	_
43-15	6860-6863	any	_
43-16	6864-6871	angular	_
43-17	6872-6878	motion	_
43-18	6879-6885	during	_
43-19	6886-6889	the	_
43-20	6890-6894	scan	_
43-21	6895-6899	were	_
43-22	6900-6910	eliminated	_
43-23	6911-6915	from	_
43-24	6916-6919	the	_
43-25	6920-6928	analysis	_
43-26	6929-6930	.	_

Text=Data of 2 IGD subjects, 4 AUD subjects and 3 HCs were excluded from functional connectivity analysis according to this criterion.
44-1	6931-6935	Data	_
44-2	6936-6938	of	_
44-3	6939-6940	2	_
44-4	6941-6944	IGD	_
44-5	6945-6953	subjects	_
44-6	6954-6955	,	_
44-7	6956-6957	4	_
44-8	6958-6961	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
44-9	6962-6970	subjects	_
44-10	6971-6974	and	_
44-11	6975-6976	3	_
44-12	6977-6980	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
44-13	6981-6985	were	_
44-14	6986-6994	excluded	_
44-15	6995-6999	from	_
44-16	7000-7010	functional	_
44-17	7011-7023	connectivity	_
44-18	7024-7032	analysis	_
44-19	7033-7042	according	_
44-20	7043-7045	to	_
44-21	7046-7050	this	_
44-22	7051-7060	criterion	_
44-23	7061-7062	.	_

Text=Then, all data were spatially normalized to MNI space and were smoothed with 4-mm FWHM Gaussian kernel.
45-1	7063-7067	Then	_
45-2	7068-7069	,	_
45-3	7070-7073	all	_
45-4	7074-7078	data	_
45-5	7079-7083	were	_
45-6	7084-7093	spatially	_
45-7	7094-7104	normalized	_
45-8	7105-7107	to	_
45-9	7108-7111	MNI	_
45-10	7112-7117	space	_
45-11	7118-7121	and	_
45-12	7122-7126	were	_
45-13	7127-7135	smoothed	_
45-14	7136-7140	with	_
45-15	7141-7145	4-mm	_
45-16	7146-7150	FWHM	_
45-17	7151-7159	Gaussian	_
45-18	7160-7166	kernel	_
45-19	7167-7168	.	_

Text=The images were subsequently detrended to remove linear trends and temporally band-pass filtered (0.01–0.08 Hz) to remove physiological and high frequency noise.
46-1	7169-7172	The	_
46-2	7173-7179	images	_
46-3	7180-7184	were	_
46-4	7185-7197	subsequently	_
46-5	7198-7207	detrended	_
46-6	7208-7210	to	_
46-7	7211-7217	remove	_
46-8	7218-7224	linear	_
46-9	7225-7231	trends	_
46-10	7232-7235	and	_
46-11	7236-7246	temporally	_
46-12	7247-7256	band-pass	_
46-13	7257-7265	filtered	_
46-14	7266-7267	(	_
46-15	7268-7277	0.01–0.08	_
46-16	7278-7280	Hz	_
46-17	7281-7282	)	_
46-18	7283-7285	to	_
46-19	7286-7292	remove	_
46-20	7293-7306	physiological	_
46-21	7307-7310	and	_
46-22	7311-7315	high	_
46-23	7316-7325	frequency	_
46-24	7326-7331	noise	_
46-25	7332-7333	.	_

Text=Friston 24 motion parameters, global signal, WM signal and CSF signal were regressed out as nuisance signals from the filtered images of each participant.
47-1	7334-7341	Friston	_
47-2	7342-7344	24	_
47-3	7345-7351	motion	_
47-4	7352-7362	parameters	_
47-5	7363-7364	,	_
47-6	7365-7371	global	_
47-7	7372-7378	signal	_
47-8	7379-7380	,	_
47-9	7381-7383	WM	_
47-10	7384-7390	signal	_
47-11	7391-7394	and	_
47-12	7395-7398	CSF	_
47-13	7399-7405	signal	_
47-14	7406-7410	were	_
47-15	7411-7420	regressed	_
47-16	7421-7424	out	_
47-17	7425-7427	as	_
47-18	7428-7436	nuisance	_
47-19	7437-7444	signals	_
47-20	7445-7449	from	_
47-21	7450-7453	the	_
47-22	7454-7462	filtered	_
47-23	7463-7469	images	_
47-24	7470-7472	of	_
47-25	7473-7477	each	_
47-26	7478-7489	participant	_
47-27	7490-7491	.	_

Text=Additionally, to remove the potential confounding effects of micro-movements on resting-state functional connectivity, we applied scrubbing for each motion-outlier.
48-1	7492-7504	Additionally	_
48-2	7505-7506	,	_
48-3	7507-7509	to	_
48-4	7510-7516	remove	_
48-5	7517-7520	the	_
48-6	7521-7530	potential	_
48-7	7531-7542	confounding	_
48-8	7543-7550	effects	_
48-9	7551-7553	of	_
48-10	7554-7569	micro-movements	_
48-11	7570-7572	on	_
48-12	7573-7586	resting-state	_
48-13	7587-7597	functional	_
48-14	7598-7610	connectivity	_
48-15	7611-7612	,	_
48-16	7613-7615	we	_
48-17	7616-7623	applied	_
48-18	7624-7633	scrubbing	_
48-19	7634-7637	for	_
48-20	7638-7642	each	_
48-21	7643-7657	motion-outlier	_
48-22	7658-7659	.	_

Text=Frames that had> 0.5 mm displacement from the previous frame were flagged and removed from subsequent analysis.
49-1	7660-7666	Frames	_
49-2	7667-7671	that	_
49-3	7672-7675	had	_
49-4	7676-7677	>	_
49-5	7678-7681	0.5	_
49-6	7682-7684	mm	_
49-7	7685-7697	displacement	_
49-8	7698-7702	from	_
49-9	7703-7706	the	_
49-10	7707-7715	previous	_
49-11	7716-7721	frame	_
49-12	7722-7726	were	_
49-13	7727-7734	flagged	_
49-14	7735-7738	and	_
49-15	7739-7746	removed	_
49-16	7747-7751	from	_
49-17	7752-7762	subsequent	_
49-18	7763-7771	analysis	_
49-19	7772-7773	.	_

Text=The mean framewise displacement (FD) in the entire fMRI scans were 0.168 ± 0.05 before scrubbing and 0.156 ± 0.04 after scrubbing.
50-1	7774-7777	The	_
50-2	7778-7782	mean	_
50-3	7783-7792	framewise	_
50-4	7793-7805	displacement	_
50-5	7806-7807	(	_
50-6	7808-7810	FD	_
50-7	7811-7812	)	_
50-8	7813-7815	in	_
50-9	7816-7819	the	_
50-10	7820-7826	entire	_
50-11	7827-7831	fMRI	_
50-12	7832-7837	scans	_
50-13	7838-7842	were	_
50-14	7843-7848	0.168	_
50-15	7849-7850	±	_
50-16	7851-7855	0.05	_
50-17	7856-7862	before	_
50-18	7863-7872	scrubbing	_
50-19	7873-7876	and	_
50-20	7877-7882	0.156	_
50-21	7883-7884	±	_
50-22	7885-7889	0.04	_
50-23	7890-7895	after	_
50-24	7896-7905	scrubbing	_
50-25	7906-7907	.	_

Text=There were no significant differences in mean FD among three groups both before and after scrubbing (χ 2 = 0.680, p = 0.712, χ 2 = 0.843, p = 0.656).
51-1	7908-7913	There	_
51-2	7914-7918	were	_
51-3	7919-7921	no	_
51-4	7922-7933	significant	_
51-5	7934-7945	differences	_
51-6	7946-7948	in	_
51-7	7949-7953	mean	_
51-8	7954-7956	FD	_
51-9	7957-7962	among	_
51-10	7963-7968	three	_
51-11	7969-7975	groups	_
51-12	7976-7980	both	_
51-13	7981-7987	before	_
51-14	7988-7991	and	_
51-15	7992-7997	after	_
51-16	7998-8007	scrubbing	_
51-17	8008-8009	(	_
51-18	8010-8011	χ	_
51-19	8012-8013	2	_
51-20	8014-8015	=	_
51-21	8016-8021	0.680	_
51-22	8022-8023	,	_
51-23	8024-8025	p	_
51-24	8026-8027	=	_
51-25	8028-8033	0.712	_
51-26	8034-8035	,	_
51-27	8036-8037	χ	_
51-28	8038-8039	2	_
51-29	8040-8041	=	_
51-30	8042-8047	0.843	_
51-31	8048-8049	,	_
51-32	8050-8051	p	_
51-33	8052-8053	=	_
51-34	8054-8059	0.656	_
51-35	8060-8061	)	_
51-36	8062-8063	.	_

Text=After scrubbing, 97.9 ± 2.6% frames on average remained (at least 155 frames, ~7 min or more), and there was no group difference in the percentage of remaining frames (IGD: 97.5 ± 3.0%; AUD: 97.9 ± 2.7%; HCs: 98.1 ± 2.4%; χ 2 = 0.126, p = 0.939).
52-1	8064-8069	After	_
52-2	8070-8079	scrubbing	_
52-3	8080-8081	,	_
52-4	8082-8086	97.9	_
52-5	8087-8088	±	_
52-6	8089-8092	2.6	_
52-7	8093-8094	%	_
52-8	8095-8101	frames	_
52-9	8102-8104	on	_
52-10	8105-8112	average	_
52-11	8113-8121	remained	_
52-12	8122-8123	(	_
52-13	8124-8126	at	_
52-14	8127-8132	least	_
52-15	8133-8136	155	_
52-16	8137-8143	frames	_
52-17	8144-8145	,	_
52-18	8146-8148	~7	_
52-19	8149-8152	min	_
52-20	8153-8155	or	_
52-21	8156-8160	more	_
52-22	8161-8162	)	_
52-23	8163-8164	,	_
52-24	8165-8168	and	_
52-25	8169-8174	there	_
52-26	8175-8178	was	_
52-27	8179-8181	no	_
52-28	8182-8187	group	_
52-29	8188-8198	difference	_
52-30	8199-8201	in	_
52-31	8202-8205	the	_
52-32	8206-8216	percentage	_
52-33	8217-8219	of	_
52-34	8220-8229	remaining	_
52-35	8230-8236	frames	_
52-36	8237-8238	(	_
52-37	8239-8242	IGD	_
52-38	8243-8244	:	_
52-39	8245-8249	97.5	_
52-40	8250-8251	±	_
52-41	8252-8255	3.0	_
52-42	8256-8257	%	_
52-43	8258-8259	;	_
52-44	8260-8263	AUD	_
52-45	8264-8265	:	_
52-46	8266-8270	97.9	_
52-47	8271-8272	±	_
52-48	8273-8276	2.7	_
52-49	8277-8278	%	_
52-50	8279-8280	;	_
52-51	8281-8284	HCs	_
52-52	8285-8286	:	_
52-53	8287-8291	98.1	_
52-54	8292-8293	±	_
52-55	8294-8297	2.4	_
52-56	8298-8299	%	_
52-57	8300-8301	;	_
52-58	8302-8303	χ	_
52-59	8304-8305	2	_
52-60	8306-8307	=	_
52-61	8308-8313	0.126	_
52-62	8314-8315	,	_
52-63	8316-8317	p	_
52-64	8318-8319	=	_
52-65	8320-8325	0.939	_
52-66	8326-8327	)	_
52-67	8328-8329	.	_

Text=Region showing significantly altered gray matter volume in IGD, the bilateral hippocampus/amygdala, was defined as seed ROI for the resting-state functional connectivity analysis A seed reference time course was obtained by averaging the time series of all voxels in the ROI, then Pearson ’ s correlation analysis was performed between the seed reference time course and the time series from the whole brain in a voxel-wise way.
53-1	8330-8336	Region	_
53-2	8337-8344	showing	_
53-3	8345-8358	significantly	_
53-4	8359-8366	altered	_
53-5	8367-8371	gray	_
53-6	8372-8378	matter	_
53-7	8379-8385	volume	_
53-8	8386-8388	in	_
53-9	8389-8392	IGD	_
53-10	8393-8394	,	_
53-11	8395-8398	the	_
53-12	8399-8408	bilateral	_
53-13	8409-8429	hippocampus/amygdala	_
53-14	8430-8431	,	_
53-15	8432-8435	was	_
53-16	8436-8443	defined	_
53-17	8444-8446	as	_
53-18	8447-8451	seed	_
53-19	8452-8455	ROI	_
53-20	8456-8459	for	_
53-21	8460-8463	the	_
53-22	8464-8477	resting-state	_
53-23	8478-8488	functional	_
53-24	8489-8501	connectivity	_
53-25	8502-8510	analysis	_
53-26	8511-8512	A	_
53-27	8513-8517	seed	_
53-28	8518-8527	reference	_
53-29	8528-8532	time	_
53-30	8533-8539	course	_
53-31	8540-8543	was	_
53-32	8544-8552	obtained	_
53-33	8553-8555	by	_
53-34	8556-8565	averaging	_
53-35	8566-8569	the	_
53-36	8570-8574	time	_
53-37	8575-8581	series	_
53-38	8582-8584	of	_
53-39	8585-8588	all	_
53-40	8589-8595	voxels	_
53-41	8596-8598	in	_
53-42	8599-8602	the	_
53-43	8603-8606	ROI	_
53-44	8607-8608	,	_
53-45	8609-8613	then	_
53-46	8614-8621	Pearson	_
53-47	8622-8623	’	_
53-48	8624-8625	s	_
53-49	8626-8637	correlation	_
53-50	8638-8646	analysis	_
53-51	8647-8650	was	_
53-52	8651-8660	performed	_
53-53	8661-8668	between	_
53-54	8669-8672	the	_
53-55	8673-8677	seed	_
53-56	8678-8687	reference	_
53-57	8688-8692	time	_
53-58	8693-8699	course	_
53-59	8700-8703	and	_
53-60	8704-8707	the	_
53-61	8708-8712	time	_
53-62	8713-8719	series	_
53-63	8720-8724	from	_
53-64	8725-8728	the	_
53-65	8729-8734	whole	_
53-66	8735-8740	brain	_
53-67	8741-8743	in	_
53-68	8744-8745	a	_
53-69	8746-8756	voxel-wise	_
53-70	8757-8760	way	_
53-71	8761-8762	.	_

Text=The correlation coefficients were converted to z values using Fisher ’ s r-to-z transformation.
54-1	8763-8766	The	_
54-2	8767-8778	correlation	_
54-3	8779-8791	coefficients	_
54-4	8792-8796	were	_
54-5	8797-8806	converted	_
54-6	8807-8809	to	_
54-7	8810-8811	z	_
54-8	8812-8818	values	_
54-9	8819-8824	using	_
54-10	8825-8831	Fisher	_
54-11	8832-8833	’	_
54-12	8834-8835	s	_
54-13	8836-8842	r-to-z	_
54-14	8843-8857	transformation	_
54-15	8858-8859	.	_

Text=Neuropsychological assessments To investigate correlations with cortical changes, we conducted comprehensive neuropsychological testing includes following; the verbal fluency test, which tests the ability to generate words in response to a letter cue and assesses cognitive fluency; the Stroop Color and Word Test, which assess sustained and selective attention, cognitive inhibition and working memory; the Trail Making Test, which assesses motor planning and cognitive shifting.
55-1	8860-8878	Neuropsychological	_
55-2	8879-8890	assessments	_
55-3	8891-8893	To	_
55-4	8894-8905	investigate	_
55-5	8906-8918	correlations	_
55-6	8919-8923	with	_
55-7	8924-8932	cortical	_
55-8	8933-8940	changes	_
55-9	8941-8942	,	_
55-10	8943-8945	we	_
55-11	8946-8955	conducted	_
55-12	8956-8969	comprehensive	_
55-13	8970-8988	neuropsychological	_
55-14	8989-8996	testing	_
55-15	8997-9005	includes	_
55-16	9006-9015	following	_
55-17	9016-9017	;	_
55-18	9018-9021	the	_
55-19	9022-9028	verbal	_
55-20	9029-9036	fluency	_
55-21	9037-9041	test	http://maven.renci.org/NeuroBridge/neurobridge#GlucoseToleranceTest
55-22	9042-9043	,	_
55-23	9044-9049	which	_
55-24	9050-9055	tests	_
55-25	9056-9059	the	_
55-26	9060-9067	ability	_
55-27	9068-9070	to	_
55-28	9071-9079	generate	_
55-29	9080-9085	words	_
55-30	9086-9088	in	_
55-31	9089-9097	response	_
55-32	9098-9100	to	_
55-33	9101-9102	a	_
55-34	9103-9109	letter	_
55-35	9110-9113	cue	_
55-36	9114-9117	and	_
55-37	9118-9126	assesses	_
55-38	9127-9136	cognitive	_
55-39	9137-9144	fluency	_
55-40	9145-9146	;	_
55-41	9147-9150	the	_
55-42	9151-9157	Stroop	_
55-43	9158-9163	Color	http://maven.renci.org/NeuroBridge/neurobridge#ControlledOralWordAssociationTestOfTheMultilingualAphasiaExamination
55-44	9164-9167	and	http://maven.renci.org/NeuroBridge/neurobridge#ControlledOralWordAssociationTestOfTheMultilingualAphasiaExamination
55-45	9168-9172	Word	http://maven.renci.org/NeuroBridge/neurobridge#ControlledOralWordAssociationTestOfTheMultilingualAphasiaExamination
55-46	9173-9177	Test	http://maven.renci.org/NeuroBridge/neurobridge#ControlledOralWordAssociationTestOfTheMultilingualAphasiaExamination
55-47	9178-9179	,	_
55-48	9180-9185	which	_
55-49	9186-9192	assess	_
55-50	9193-9202	sustained	_
55-51	9203-9206	and	_
55-52	9207-9216	selective	_
55-53	9217-9226	attention	_
55-54	9227-9228	,	_
55-55	9229-9238	cognitive	_
55-56	9239-9249	inhibition	_
55-57	9250-9253	and	_
55-58	9254-9261	working	_
55-59	9262-9268	memory	_
55-60	9269-9270	;	_
55-61	9271-9274	the	_
55-62	9275-9280	Trail	http://maven.renci.org/NeuroBridge/neurobridge#GlucoseToleranceTest
55-63	9281-9287	Making	http://maven.renci.org/NeuroBridge/neurobridge#GlucoseToleranceTest
55-64	9288-9292	Test	http://maven.renci.org/NeuroBridge/neurobridge#GlucoseToleranceTest
55-65	9293-9294	,	_
55-66	9295-9300	which	_
55-67	9301-9309	assesses	_
55-68	9310-9315	motor	_
55-69	9316-9324	planning	_
55-70	9325-9328	and	_
55-71	9329-9338	cognitive	_
55-72	9339-9347	shifting	_
55-73	9348-9349	.	_

Text=Also, three executive function subtests of the Cambridge Neuropsychological Test Automated Battery (CANTAB) were performed; the Intra-Extra Dimensional Set Shift test, a computerised analogue of the Wisconsin Card Sorting Test used to assess the ability to shift and flexibly allocate attention; the Stockings of Cambridge test, which assess spatial planning based upon the Tower of Hanoi test; and the SSP, a visuo-spatial analog of the Digit Span test used to assess working memory capacity.
56-1	9350-9354	Also	_
56-2	9355-9356	,	_
56-3	9357-9362	three	_
56-4	9363-9372	executive	_
56-5	9373-9381	function	_
56-6	9382-9390	subtests	_
56-7	9391-9393	of	_
56-8	9394-9397	the	_
56-9	9398-9407	Cambridge	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
56-10	9408-9426	Neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
56-11	9427-9431	Test	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
56-12	9432-9441	Automated	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
56-13	9442-9449	Battery	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
56-14	9450-9451	(	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
56-15	9452-9458	CANTAB	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
56-16	9459-9460	)	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
56-17	9461-9465	were	_
56-18	9466-9475	performed	_
56-19	9476-9477	;	_
56-20	9478-9481	the	_
56-21	9482-9493	Intra-Extra	_
56-22	9494-9505	Dimensional	_
56-23	9506-9509	Set	_
56-24	9510-9515	Shift	_
56-25	9516-9520	test	_
56-26	9521-9522	,	_
56-27	9523-9524	a	_
56-28	9525-9537	computerised	_
56-29	9538-9546	analogue	_
56-30	9547-9549	of	_
56-31	9550-9553	the	_
56-32	9554-9563	Wisconsin	_
56-33	9564-9568	Card	_
56-34	9569-9576	Sorting	_
56-35	9577-9581	Test	http://maven.renci.org/NeuroBridge/neurobridge#GlucoseToleranceTest
56-36	9582-9586	used	_
56-37	9587-9589	to	_
56-38	9590-9596	assess	_
56-39	9597-9600	the	_
56-40	9601-9608	ability	_
56-41	9609-9611	to	_
56-42	9612-9617	shift	_
56-43	9618-9621	and	_
56-44	9622-9630	flexibly	_
56-45	9631-9639	allocate	_
56-46	9640-9649	attention	_
56-47	9650-9651	;	_
56-48	9652-9655	the	_
56-49	9656-9665	Stockings	_
56-50	9666-9668	of	_
56-51	9669-9678	Cambridge	_
56-52	9679-9683	test	_
56-53	9684-9685	,	_
56-54	9686-9691	which	_
56-55	9692-9698	assess	_
56-56	9699-9706	spatial	_
56-57	9707-9715	planning	_
56-58	9716-9721	based	_
56-59	9722-9726	upon	_
56-60	9727-9730	the	_
56-61	9731-9736	Tower	_
56-62	9737-9739	of	_
56-63	9740-9745	Hanoi	_
56-64	9746-9750	test	_
56-65	9751-9752	;	_
56-66	9753-9756	and	_
56-67	9757-9760	the	_
56-68	9761-9764	SSP	_
56-69	9765-9766	,	_
56-70	9767-9768	a	_
56-71	9769-9782	visuo-spatial	_
56-72	9783-9789	analog	_
56-73	9790-9792	of	_
56-74	9793-9796	the	_
56-75	9797-9802	Digit	_
56-76	9803-9807	Span	_
56-77	9808-9812	test	_
56-78	9813-9817	used	_
56-79	9818-9820	to	_
56-80	9821-9827	assess	_
56-81	9828-9835	working	_
56-82	9836-9842	memory	_
56-83	9843-9851	capacity	_
56-84	9852-9853	.	_

Text=Statistical analyses To evaluate differences between groups in gray matter volume and thickness, statistical tests were performed using a one-way analysis of covariance (ANCOVA) with diagnostic group (IGD, AUD, and HCs) as the factor of interest, followed by post-hoc, two-sample t-test.
57-1	9854-9865	Statistical	_
57-2	9866-9874	analyses	_
57-3	9875-9877	To	_
57-4	9878-9886	evaluate	_
57-5	9887-9898	differences	_
57-6	9899-9906	between	_
57-7	9907-9913	groups	_
57-8	9914-9916	in	_
57-9	9917-9921	gray	_
57-10	9922-9928	matter	_
57-11	9929-9935	volume	_
57-12	9936-9939	and	_
57-13	9940-9949	thickness	_
57-14	9950-9951	,	_
57-15	9952-9963	statistical	_
57-16	9964-9969	tests	_
57-17	9970-9974	were	_
57-18	9975-9984	performed	_
57-19	9985-9990	using	_
57-20	9991-9992	a	_
57-21	9993-10000	one-way	_
57-22	10001-10009	analysis	_
57-23	10010-10012	of	_
57-24	10013-10023	covariance	_
57-25	10024-10025	(	_
57-26	10026-10032	ANCOVA	_
57-27	10033-10034	)	_
57-28	10035-10039	with	_
57-29	10040-10050	diagnostic	_
57-30	10051-10056	group	_
57-31	10057-10058	(	_
57-32	10059-10062	IGD	_
57-33	10063-10064	,	_
57-34	10065-10068	AUD	_
57-35	10069-10070	,	_
57-36	10071-10074	and	_
57-37	10075-10078	HCs	_
57-38	10079-10080	)	_
57-39	10081-10083	as	_
57-40	10084-10087	the	_
57-41	10088-10094	factor	_
57-42	10095-10097	of	_
57-43	10098-10106	interest	_
57-44	10107-10108	,	_
57-45	10109-10117	followed	_
57-46	10118-10120	by	_
57-47	10121-10129	post-hoc	_
57-48	10130-10131	,	_
57-49	10132-10142	two-sample	_
57-50	10143-10149	t-test	_
57-51	10150-10151	.	_

Text=Due to significant between-group differences in age and IQ, these variables were included as covariates of no interest in both the cortical volume and thickness analyses.
58-1	10152-10155	Due	_
58-2	10156-10158	to	_
58-3	10159-10170	significant	_
58-4	10171-10184	between-group	_
58-5	10185-10196	differences	_
58-6	10197-10199	in	_
58-7	10200-10203	age	_
58-8	10204-10207	and	_
58-9	10208-10210	IQ	_
58-10	10211-10212	,	_
58-11	10213-10218	these	_
58-12	10219-10228	variables	_
58-13	10229-10233	were	_
58-14	10234-10242	included	_
58-15	10243-10245	as	_
58-16	10246-10256	covariates	_
58-17	10257-10259	of	_
58-18	10260-10262	no	_
58-19	10263-10271	interest	_
58-20	10272-10274	in	_
58-21	10275-10279	both	_
58-22	10280-10283	the	_
58-23	10284-10292	cortical	_
58-24	10293-10299	volume	_
58-25	10300-10303	and	_
58-26	10304-10313	thickness	_
58-27	10314-10322	analyses	_
58-28	10323-10324	.	_

Text=Total intracranial volume also included as a covariate of no interest for the VBM analysis.
59-1	10325-10330	Total	_
59-2	10331-10343	intracranial	_
59-3	10344-10350	volume	_
59-4	10351-10355	also	_
59-5	10356-10364	included	_
59-6	10365-10367	as	_
59-7	10368-10369	a	_
59-8	10370-10379	covariate	_
59-9	10380-10382	of	_
59-10	10383-10385	no	_
59-11	10386-10394	interest	_
59-12	10395-10398	for	_
59-13	10399-10402	the	_
59-14	10403-10406	VBM	_
59-15	10407-10415	analysis	_
59-16	10416-10417	.	_

Text=Analyses were corrected for multiple comparisons by means of cluster-size inferences using Monte Carlo simulations.
60-1	10418-10426	Analyses	_
60-2	10427-10431	were	_
60-3	10432-10441	corrected	_
60-4	10442-10445	for	_
60-5	10446-10454	multiple	_
60-6	10455-10466	comparisons	_
60-7	10467-10469	by	_
60-8	10470-10475	means	_
60-9	10476-10478	of	_
60-10	10479-10491	cluster-size	_
60-11	10492-10502	inferences	_
60-12	10503-10508	using	_
60-13	10509-10514	Monte	_
60-14	10515-10520	Carlo	_
60-15	10521-10532	simulations	_
60-16	10533-10534	.	_

Text=The AlphaSim program in the rest software (http: //restfmri.net) was used for the VBM analysis and a precomputed Monte Carlo simulation implemented by FreeSurfer was used for the thickness analysis.
61-1	10535-10538	The	_
61-2	10539-10547	AlphaSim	_
61-3	10548-10555	program	_
61-4	10556-10558	in	_
61-5	10559-10562	the	_
61-6	10563-10567	rest	_
61-7	10568-10576	software	_
61-8	10577-10578	(	_
61-9	10579-10583	http	_
61-10	10584-10585	:	_
61-11	10586-10600	//restfmri.net	_
61-12	10601-10602	)	_
61-13	10603-10606	was	_
61-14	10607-10611	used	_
61-15	10612-10615	for	_
61-16	10616-10619	the	_
61-17	10620-10623	VBM	_
61-18	10624-10632	analysis	_
61-19	10633-10636	and	_
61-20	10637-10638	a	_
61-21	10639-10650	precomputed	_
61-22	10651-10656	Monte	_
61-23	10657-10662	Carlo	_
61-24	10663-10673	simulation	_
61-25	10674-10685	implemented	_
61-26	10686-10688	by	_
61-27	10689-10699	FreeSurfer	_
61-28	10700-10703	was	_
61-29	10704-10708	used	_
61-30	10709-10712	for	_
61-31	10713-10716	the	_
61-32	10717-10726	thickness	_
61-33	10727-10735	analysis	_
61-34	10736-10737	.	_

Text=The initial cluster-forming threshold employed in the present study was p = 0.005, and α = 0.05.
62-1	10738-10741	The	_
62-2	10742-10749	initial	_
62-3	10750-10765	cluster-forming	_
62-4	10766-10775	threshold	_
62-5	10776-10784	employed	_
62-6	10785-10787	in	_
62-7	10788-10791	the	_
62-8	10792-10799	present	_
62-9	10800-10805	study	_
62-10	10806-10809	was	_
62-11	10810-10811	p	_
62-12	10812-10813	=	_
62-13	10814-10819	0.005	_
62-14	10820-10821	,	_
62-15	10822-10825	and	_
62-16	10826-10827	α	_
62-17	10828-10829	=	_
62-18	10830-10834	0.05	_
62-19	10835-10836	.	_

Text=For the functional connectivity analysis, one-sample t-tests were conducted on the individual connectivity maps of the three groups separately, thresholded leniently at a voxel-level threshold of p <0.05 and a cluster size threshold of more than 491 voxels.
63-1	10837-10840	For	_
63-2	10841-10844	the	_
63-3	10845-10855	functional	_
63-4	10856-10868	connectivity	_
63-5	10869-10877	analysis	_
63-6	10878-10879	,	_
63-7	10880-10890	one-sample	_
63-8	10891-10898	t-tests	_
63-9	10899-10903	were	_
63-10	10904-10913	conducted	_
63-11	10914-10916	on	_
63-12	10917-10920	the	_
63-13	10921-10931	individual	_
63-14	10932-10944	connectivity	_
63-15	10945-10949	maps	_
63-16	10950-10952	of	_
63-17	10953-10956	the	_
63-18	10957-10962	three	_
63-19	10963-10969	groups	_
63-20	10970-10980	separately	_
63-21	10981-10982	,	_
63-22	10983-10994	thresholded	_
63-23	10995-11004	leniently	_
63-24	11005-11007	at	_
63-25	11008-11009	a	_
63-26	11010-11021	voxel-level	_
63-27	11022-11031	threshold	_
63-28	11032-11034	of	_
63-29	11035-11036	p	_
63-30	11037-11038	<	_
63-31	11039-11043	0.05	_
63-32	11044-11047	and	_
63-33	11048-11049	a	_
63-34	11050-11057	cluster	_
63-35	11058-11062	size	_
63-36	11063-11072	threshold	_
63-37	11073-11075	of	_
63-38	11076-11080	more	_
63-39	11081-11085	than	_
63-40	11086-11089	491	_
63-41	11090-11096	voxels	_
63-42	11097-11098	.	_

Text=To compare the functional connectivity maps between the three groups, statistical tests were performed using an ANCOVA with diagnostic group as the factor of interests and age and IQ included as covariates of no interests followed by post-hoc, two-sample t-test.
64-1	11099-11101	To	_
64-2	11102-11109	compare	_
64-3	11110-11113	the	_
64-4	11114-11124	functional	_
64-5	11125-11137	connectivity	_
64-6	11138-11142	maps	_
64-7	11143-11150	between	_
64-8	11151-11154	the	_
64-9	11155-11160	three	_
64-10	11161-11167	groups	_
64-11	11168-11169	,	_
64-12	11170-11181	statistical	_
64-13	11182-11187	tests	_
64-14	11188-11192	were	_
64-15	11193-11202	performed	_
64-16	11203-11208	using	_
64-17	11209-11211	an	_
64-18	11212-11218	ANCOVA	_
64-19	11219-11223	with	_
64-20	11224-11234	diagnostic	_
64-21	11235-11240	group	_
64-22	11241-11243	as	_
64-23	11244-11247	the	_
64-24	11248-11254	factor	_
64-25	11255-11257	of	_
64-26	11258-11267	interests	_
64-27	11268-11271	and	_
64-28	11272-11275	age	_
64-29	11276-11279	and	_
64-30	11280-11282	IQ	_
64-31	11283-11291	included	_
64-32	11292-11294	as	_
64-33	11295-11305	covariates	_
64-34	11306-11308	of	_
64-35	11309-11311	no	_
64-36	11312-11321	interests	_
64-37	11322-11330	followed	_
64-38	11331-11333	by	_
64-39	11334-11342	post-hoc	_
64-40	11343-11344	,	_
64-41	11345-11355	two-sample	_
64-42	11356-11362	t-test	_
64-43	11363-11364	.	_

Text=The significant level was set at p <0.005 using AlphaSim correction (α = 0.05).
65-1	11365-11368	The	_
65-2	11369-11380	significant	_
65-3	11381-11386	level	_
65-4	11387-11390	was	_
65-5	11391-11394	set	_
65-6	11395-11397	at	_
65-7	11398-11399	p	_
65-8	11400-11401	<	_
65-9	11402-11407	0.005	_
65-10	11408-11413	using	_
65-11	11414-11422	AlphaSim	_
65-12	11423-11433	correction	_
65-13	11434-11435	(	_
65-14	11436-11437	α	_
65-15	11438-11439	=	_
65-16	11440-11444	0.05	_
65-17	11445-11446	)	_
65-18	11447-11448	.	_

Text=The two-sample t-test was masked with a map defined by a one-sample t-test of each relevant group.
66-1	11449-11452	The	_
66-2	11453-11463	two-sample	_
66-3	11464-11470	t-test	_
66-4	11471-11474	was	_
66-5	11475-11481	masked	_
66-6	11482-11486	with	_
66-7	11487-11488	a	_
66-8	11489-11492	map	_
66-9	11493-11500	defined	_
66-10	11501-11503	by	_
66-11	11504-11505	a	_
66-12	11506-11516	one-sample	_
66-13	11517-11523	t-test	_
66-14	11524-11526	of	_
66-15	11527-11531	each	_
66-16	11532-11540	relevant	_
66-17	11541-11546	group	_
66-18	11547-11548	.	_

Text=Demographic characteristics and scores on neuropsychological tests were evaluated for normality using Shapiro-Wilk.
67-1	11549-11560	Demographic	_
67-2	11561-11576	characteristics	_
67-3	11577-11580	and	_
67-4	11581-11587	scores	_
67-5	11588-11590	on	_
67-6	11591-11609	neuropsychological	_
67-7	11610-11615	tests	_
67-8	11616-11620	were	_
67-9	11621-11630	evaluated	_
67-10	11631-11634	for	_
67-11	11635-11644	normality	_
67-12	11645-11650	using	_
67-13	11651-11663	Shapiro-Wilk	_
67-14	11664-11665	.	_

Text=If normality was justified, one-way analyses of variance (ANOVA) was carried out with Tukey ’ s HSD post-hoc tests.
68-1	11666-11668	If	_
68-2	11669-11678	normality	_
68-3	11679-11682	was	_
68-4	11683-11692	justified	_
68-5	11693-11694	,	_
68-6	11695-11702	one-way	_
68-7	11703-11711	analyses	_
68-8	11712-11714	of	_
68-9	11715-11723	variance	_
68-10	11724-11725	(	_
68-11	11726-11731	ANOVA	_
68-12	11732-11733	)	_
68-13	11734-11737	was	_
68-14	11738-11745	carried	_
68-15	11746-11749	out	_
68-16	11750-11754	with	_
68-17	11755-11760	Tukey	_
68-18	11761-11762	’	_
68-19	11763-11764	s	_
68-20	11765-11768	HSD	_
68-21	11769-11777	post-hoc	_
68-22	11778-11783	tests	_
68-23	11784-11785	.	_

Text=When normality was violated, Kruskal-Wallis tests with Mann–Whitney U post-hoc tests were used to evaluate group differences.
69-1	11786-11790	When	_
69-2	11791-11800	normality	_
69-3	11801-11804	was	_
69-4	11805-11813	violated	_
69-5	11814-11815	,	_
69-6	11816-11830	Kruskal-Wallis	_
69-7	11831-11836	tests	_
69-8	11837-11841	with	_
69-9	11842-11854	Mann–Whitney	_
69-10	11855-11856	U	_
69-11	11857-11865	post-hoc	_
69-12	11866-11871	tests	_
69-13	11872-11876	were	_
69-14	11877-11881	used	_
69-15	11882-11884	to	_
69-16	11885-11893	evaluate	_
69-17	11894-11899	group	_
69-18	11900-11911	differences	_
69-19	11912-11913	.	_

Text=Statistical analyses were performed using SPSS 13.0.
70-1	11914-11925	Statistical	_
70-2	11926-11934	analyses	_
70-3	11935-11939	were	_
70-4	11940-11949	performed	_
70-5	11950-11955	using	_
70-6	11956-11960	SPSS	_
70-7	11961-11965	13.0	_
70-8	11966-11967	.	_

Text=Additionally, we examined the relationship between brain cortical data and clinical characteristics in each addiction group (duration of illness; AUDIT-K score, and number of standard drinks for the AUD group; IAT score and mean hours using Internet games per day for the IGD group) and scores on neuropsychological tests showing significant differences between groups using regression analyses of the whole-brain volume or cortical thickness imaging.
71-1	11968-11980	Additionally	_
71-2	11981-11982	,	_
71-3	11983-11985	we	_
71-4	11986-11994	examined	_
71-5	11995-11998	the	_
71-6	11999-12011	relationship	_
71-7	12012-12019	between	_
71-8	12020-12025	brain	_
71-9	12026-12034	cortical	_
71-10	12035-12039	data	_
71-11	12040-12043	and	_
71-12	12044-12052	clinical	_
71-13	12053-12068	characteristics	_
71-14	12069-12071	in	_
71-15	12072-12076	each	_
71-16	12077-12086	addiction	_
71-17	12087-12092	group	_
71-18	12093-12094	(	_
71-19	12095-12103	duration	_
71-20	12104-12106	of	_
71-21	12107-12114	illness	_
71-22	12115-12116	;	_
71-23	12117-12124	AUDIT-K	_
71-24	12125-12130	score	_
71-25	12131-12132	,	_
71-26	12133-12136	and	_
71-27	12137-12143	number	_
71-28	12144-12146	of	_
71-29	12147-12155	standard	_
71-30	12156-12162	drinks	_
71-31	12163-12166	for	_
71-32	12167-12170	the	_
71-33	12171-12174	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
71-34	12175-12180	group	_
71-35	12181-12182	;	_
71-36	12183-12186	IAT	_
71-37	12187-12192	score	_
71-38	12193-12196	and	_
71-39	12197-12201	mean	_
71-40	12202-12207	hours	_
71-41	12208-12213	using	_
71-42	12214-12222	Internet	_
71-43	12223-12228	games	_
71-44	12229-12232	per	_
71-45	12233-12236	day	_
71-46	12237-12240	for	_
71-47	12241-12244	the	_
71-48	12245-12248	IGD	_
71-49	12249-12254	group	_
71-50	12255-12256	)	_
71-51	12257-12260	and	_
71-52	12261-12267	scores	_
71-53	12268-12270	on	_
71-54	12271-12289	neuropsychological	_
71-55	12290-12295	tests	_
71-56	12296-12303	showing	_
71-57	12304-12315	significant	_
71-58	12316-12327	differences	_
71-59	12328-12335	between	_
71-60	12336-12342	groups	_
71-61	12343-12348	using	_
71-62	12349-12359	regression	_
71-63	12360-12368	analyses	_
71-64	12369-12371	of	_
71-65	12372-12375	the	_
71-66	12376-12387	whole-brain	_
71-67	12388-12394	volume	_
71-68	12395-12397	or	_
71-69	12398-12406	cortical	_
71-70	12407-12416	thickness	_
71-71	12417-12424	imaging	_
71-72	12425-12426	.	_

Text=For regression analyses, an exploratory uncorrected statistical threshold was set at p <0.005, with a minimal cluster size of 100 voxels.
72-1	12427-12430	For	_
72-2	12431-12441	regression	_
72-3	12442-12450	analyses	_
72-4	12451-12452	,	_
72-5	12453-12455	an	_
72-6	12456-12467	exploratory	_
72-7	12468-12479	uncorrected	_
72-8	12480-12491	statistical	_
72-9	12492-12501	threshold	_
72-10	12502-12505	was	_
72-11	12506-12509	set	_
72-12	12510-12512	at	_
72-13	12513-12514	p	_
72-14	12515-12516	<	_
72-15	12517-12522	0.005	_
72-16	12523-12524	,	_
72-17	12525-12529	with	_
72-18	12530-12531	a	_
72-19	12532-12539	minimal	_
72-20	12540-12547	cluster	_
72-21	12548-12552	size	_
72-22	12553-12555	of	_
72-23	12556-12559	100	_
72-24	12560-12566	voxels	_
72-25	12567-12568	.	_

Text=In the current study, we focused on the brain regions showing significantly different cortical changes between groups.
73-1	12569-12571	In	_
73-2	12572-12575	the	_
73-3	12576-12583	current	_
73-4	12584-12589	study	_
73-5	12590-12591	,	_
73-6	12592-12594	we	_
73-7	12595-12602	focused	_
73-8	12603-12605	on	_
73-9	12606-12609	the	_
73-10	12610-12615	brain	_
73-11	12616-12623	regions	_
73-12	12624-12631	showing	_
73-13	12632-12645	significantly	_
73-14	12646-12655	different	_
73-15	12656-12664	cortical	_
73-16	12665-12672	changes	_
73-17	12673-12680	between	_
73-18	12681-12687	groups	_
73-19	12688-12689	.	_

Text=Eun Jin Yoon and Jung-Seok Choi contributed equally to this work.
74-1	12690-12693	Eun	_
74-2	12694-12697	Jin	_
74-3	12698-12702	Yoon	_
74-4	12703-12706	and	_
74-5	12707-12716	Jung-Seok	_
74-6	12717-12721	Choi	_
74-7	12722-12733	contributed	_
74-8	12734-12741	equally	_
74-9	12742-12744	to	_
74-10	12745-12749	this	_
74-11	12750-12754	work	_
74-12	12755-12756	.	_

Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
75-1	12757-12766	Publisher	_
75-2	12767-12769	's	_
75-3	12770-12774	note	_
75-4	12775-12776	:	_
75-5	12777-12785	Springer	_
75-6	12786-12792	Nature	_
75-7	12793-12800	remains	_
75-8	12801-12808	neutral	_
75-9	12809-12813	with	_
75-10	12814-12820	regard	_
75-11	12821-12823	to	_
75-12	12824-12838	jurisdictional	_
75-13	12839-12845	claims	_
75-14	12846-12848	in	_
75-15	12849-12858	published	_
75-16	12859-12863	maps	_
75-17	12864-12867	and	_
75-18	12868-12881	institutional	_
75-19	12882-12894	affiliations	_
75-20	12895-12896	.	_

